Eli Lilly Cuts Sales Outlook After Sluggish Growth for Incretin Drugs

HS 14/01/2025
Advertisements




Eli Lilly cut its outlook for fourth-quarter revenue citing sluggish growth in the market for incretin, which increases insulin levels.



Source link

More Stories

Domino's Pizza stock falls on disappointing sales — and CEO thinks more chains will follow

HS 27/04/2026

Spotify teams up with Peloton to launch global fitness content hub

HS 27/04/2026

This bank CEO let his AI clone handle an earnings call — now he's signing an OpenAI deal

HS 27/04/2026

You may have missed

Jury seated in Musk v. Altman trial, with opening arguments up next

HS 27/04/2026

Rajnath lands in Kyrgyzstan to attend SCO def ministers meet, may discuss West Asia crisis | India News – The Times of India

HS 27/04/2026

Mitchell Santner ruled out of IPL 2026 as troubles pile up for Mumbai Indians

HS 27/04/2026

Lp(a) drugs from Novartis, Amgen and Eli Lilly aim to prevent heart attacks

HS 27/04/2026

Cole Allen charged with trying to assassinate Trump at WHCD event

HS 27/04/2026